.png){kind=icon}
.png){kind=icon}
Return
Antiviral drug discovery strategy based on Raman imaging technology
.png){kind=icon}
PRE
AI
L
Y
J
J
H
DOI：10.1016/j.bios.2026.118991.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• We developed a mechanism-guided antiviral screening platform based on confocal Raman microscopy (CRM), enabling label-free, quantitative, and spatially resolved assessment of antiviral candidates at the single-cell level， overcoming the trial-and-error paradigm inherent in conventional early-stage drug discovery and establishing CRM as a rapid, mechanism-informed tool for prioritizing antiviral leads and accelerating preclinical development. • The platform facilitates subcellular pharmacodynamic mapping by directly correlating virus-induced morphological alterations with spatially resolved biochemical distributions of lipids, nucleic acids, and proteins, thereby yielding mechanistic insights into antiviral drug action. • Using this CRM-driven strategy, the antiviral agent α-linolenic acid (ALA) was identified through its demonstrated capacity to restore cellular homeostasis during influenza A virus infection. • CRM was further extended to ex vivo lung tissue analysis, allowing high-resolution evaluation of alveolar architecture and pulmonary surfactant (PS) composition in influenza-infected murine lungs.
Journal
IF:
10.5
Papers:
1.8W
Citations:
7.7W
Organization
Cited Papers